Open Access

Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicts worse outcome in non-small cell lung cancer

  • Authors:
    • Xiaohui Chen
    • Yujie Deng
    • Yi Shi
    • Weifeng Zhu
    • Yibin Cai
    • Chunwei Xu
    • Kunshou Zhu
    • Xiongwei Zheng
    • Gang Chen
    • Qi Xie
    • Guoxing Weng
  • View Affiliations

  • Published online on: February 8, 2018     https://doi.org/10.3892/ol.2018.7993
  • Pages:5043-5055
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Functional inactivation of human runt‑related transcription factor 3 (RUNX3) through mutation or epigenetic silencing has been well-documented in many cancerous entities. In addition to gene mutation and promoter hypermethylation, cytoplasmic mislocalization has emerged as another major manifestation of RUNX3 dysfunction in malignancies including breast, colorectal and gastric cancers. The aim of the present study was to investigate whether patients with non‑small cell lung cancer (NSCLC) and different RUNX3 expression patterns would have different overall survival (OS), and the associations between different patterns of clinicopathological parameters and clinical outcome. Expressions of RUNX3 and Ki‑67 were immunohistochemically detected in normal lung tissue (n=5) and surgically resected tissues from NSCLC patients (n=188). The optimal cutoff of RUNX3 was determined by X‑tile software associated with their survival. Apoptotic index in cancerous tissue was evaluated using the terminal deoxynucleotidyl transferase mediated dUTP‑biotin nick end labelling method. The prognostic significance of different expression patterns of RUNX3 was determined by means of Kaplan‑Meier survival estimates and log‑rank tests. It was revealed that loss of RUNX3 expression in NSCLC was correlated with a low cancerous apoptotic index (P<0.001), shorter OS and worse prognosis (P=0.0142), while no statistical difference of apoptotic index (P=0.73) or survival (P=0.3781) was determined between patient subgroups with different localization of RUNX3 expression, which was quite different from the situation demonstrated in other malignancies. In conclusion, loss of expression rather than cytoplasmic mislocalization of RUNX3 predicted worse outcome in NSCLC, which was quite different from what manifested in other cancer types, and thus, the underlying mechanism may deserve further investigation.

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, X., Deng, Y., Shi, Y., Zhu, W., Cai, Y., Xu, C. ... Weng, G. (2018). Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicts worse outcome in non-small cell lung cancer. Oncology Letters, 15, 5043-5055. https://doi.org/10.3892/ol.2018.7993
MLA
Chen, X., Deng, Y., Shi, Y., Zhu, W., Cai, Y., Xu, C., Zhu, K., Zheng, X., Chen, G., Xie, Q., Weng, G."Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicts worse outcome in non-small cell lung cancer". Oncology Letters 15.4 (2018): 5043-5055.
Chicago
Chen, X., Deng, Y., Shi, Y., Zhu, W., Cai, Y., Xu, C., Zhu, K., Zheng, X., Chen, G., Xie, Q., Weng, G."Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicts worse outcome in non-small cell lung cancer". Oncology Letters 15, no. 4 (2018): 5043-5055. https://doi.org/10.3892/ol.2018.7993